Baxter International Articles
AEterna 1st qtr sales leap 61.3%
5 May 2003
Hassan takes biggest pay rise in 2002 CEO compensation
28 April 2003
Abbott completes bar code initiative
7 April 2003
Stock Commentary - New York
7 April 2003
Acambis gets final installment from Bxter
31 March 2003
Baxter to acquire ML Labs' icodextrin-making facility
31 March 2003
Stock Commentary - New York
24 March 2003
Baxter, Arriva trial rec alpha-1 antitrypsin
10 March 2003
Baxter gains major Canadian blood product contract
10 March 2003
New report sees big changes for global antibiotics market
10 February 2003
Baxter achieves solid growth in 2002
3 February 2003
Baxter to launch Aralast after FDA approval
20 January 2003
Round-up of pharmaceutical mergers and acquisitions during 2001
13 January 2003
Canada's AEterna buys Zentaris from Degussa
6 January 2003
Tokyo pharma stocks - 2 weeks to Dec 30
6 January 2003
Baxter acquires ESI in $305M deal
6 January 2003
CSL/Novartis Sandoglobulin deal
5 August 2002
Malaysia's Duopharma to build new facility
5 August 2002
Stock Commentary - New York
29 July 2002
Baxter's 2nd qtr sales below forecasts
29 July 2002
Baxter's 2nd-qtr sales below forecasts
29 July 2002
Baxter launches oral Mesnex
22 July 2002
Baxter starts Ph III trial of new immune globulin
22 July 2002
Baxter files in USA for albumin-free rFVIII
8 July 2002
Baxter buys Wyeth generic inj unit
17 June 2002
Baxter increases stake in Acambis
10 June 2002
Baxter outlines growth initiatives
20 May 2002
Strong earnings growth at Baxter
29 April 2002
Acambis bid rumors
15 April 2002
Argenta expand R&D
15 April 2002
Baxter expands in Europe
15 April 2002
Baxter outlines growth strategy
25 March 2002
Acambis looking to be profitable in 2002
18 March 2002
Baxter building units in Austria and Cz Rep
18 March 2002
Baxter to buy Fusion in a $157 million deal
4 March 2002
Argenta signs CNS deal with Lundbeck
4 February 2002
Synt:em and Baxter to collaborate on peptide drugs
4 February 2002
Shire gets Canadian approval for NeisVac-C.
21 January 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Acambis gets $40 mill boost from Baxter
7 December 2001
Stock Commentary - New York
6 December 2001
Baxter closes Swedish plant
29 November 2001
Stock Commentary - New York
15 November 2001
Baxter links deaths to Swedish plant
5 November 2001
Baxter completes ASTA Medica Oncology acquisition
2 November 2001
Baxter boosts oncology business with Epoetin Omega buy
17 October 2001
Croatia investigating Baxter devices
16 October 2001
RTP and Baxter enter drug delivery agreement
19 September 2001
FDA approves Baxter's 3rd suite at Bioscience facility
13 September 2001
Alliance Pharma reports higher 1st-qtr losses
11 September 2001
Alliance looking to raise $15 million
3 September 2001
Update - Baxter wins backing for new dialysis solution
21 August 2001
ML Labs gets US backing for dialysis solution
13 August 2001
Xoma initiates Ph II Neuprex trial in Crohn's
2 August 2001
Appointment at Baxter
26 July 2001
Baxter gets EU approval for Ceprotin
23 July 2001
Bigmar signs $6.9 million agreement with Baxter
2 July 2001
Cerus placement raises $78 million
18 May 2001
Stock Commentary - New York
11 April 2001
Arriva and Baxter win ruling in AAT case
10 April 2001
Baxter appointments
29 March 2001
World vaccines sales "to grow 21%/year"
23 March 2001
Baxter vaccine to combat group B meningococci
22 March 2001
Baxter/Pharming start C1 inhibitor trial
12 March 2001
Baxter favorite to buy Lublin
28 February 2001
FDA accepts Baxter's NDA for icodextrin
19 February 2001
Analysts expectant on future prospects for Canada's Axcan Pharma
13 February 2001
ML Labs looking at strategic options
22 January 2001
Argenta appointment
4 January 2001
Glaxo Wellcome signs protein pact with OGS
5 December 2000
Allergan returns rBPI rights to Xoma
17 November 2000
Cantab attracting takeover bids
3 November 2000
Stock Commentary - New York
26 October 2000
Stock Commentary Europe
28 September 2000
Baxter takes stake in Peptide Therapeutics and leaves Cantab in the cold
20 September 2000
Pharming's first half revenues leap 75%
2 August 2000
Evotec bids $475 mill for Oxford Asymmetry
31 July 2000
Quadrant signs hemophilia sugar deal
25 July 2000
Baxter wins UK approval for meng C vaccine
20 July 2000
Baxter completes NAV acquisition
29 June 2000
Baxter completes NAV acquisition
27 June 2000
CSL buys ZLB for 860 million Swiss francs
15 June 2000
Axac to sell stake in Althin to Baxter
18 May 2000
Research partners boosting Pharming
12 May 2000
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
